美国 · SEC FORM 4
Beyond Air, Inc.
XAIR · Nasdaq · CIK 0001641631 · Healthcare · Medical Devices
内部人信号
3 位买方 · 6 条买入交易行 · $287.3K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ 角色得分低 · 买入者中职位最高的是：Chief Executive Officer（CEO、董事长和持股 10% 以上的股东得分最低）
- ✓ Recent activity · latest purchase 2026-10-13
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
买方广度与集中度
Roles in the peak window: Chief Executive Officer, Chief Financial Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
最新留档分数
- 64.1
- 65.9
- 65.7
- 65.3
- 65.2
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -29.9%
- 3M
- -63.9%
- 6M
- -80.1%
- 12M
- -95.8%
波动率与流动性
- 波动率
- 155.8%
- Beta
- —
- 平均每日成交额
- USD 488,352
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- -433.0%
- ROE
- -542.8%
- 细分行业
- Medical Devices
市场数据
价格数据截至：2026-10-16 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：利润率, ROE · 财年截止日：2026-03-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 62,761
- 上期报告
- 59,321
- 日均成交量
- 119,472
- 回补天数
- ≤ 1.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Lin Yi-Chien | 买入 (P) | Common Stock | 2,607 | USD 2.21 | USD 5,761 | SEC 申报 ↗ |
| 2026-10-01 | Lin Yi-Chien | 买入 (P) | Common Stock | 15,393 | USD 2.80 | USD 43,100 | SEC 申报 ↗ |
| 2026-09-30 | Lin Yi-Chien | 买入 (P) | Common Stock | 2,000 | USD 2.71 | USD 5,420 | SEC 申报 ↗ |
| 2026-09-29 | Lin Yi-Chien | 买入 (P) | Common Stock | 3,000 | USD 2.69 | USD 8,070 | SEC 申报 ↗ |
| 2026-07-29 | MOORHEAD DANIEL J | 买入 (P) | Common Stock | 4,340 | USD 5.76 | USD 24,998 | SEC 申报 ↗ |
| 2026-07-29 | Goodman Robert Scott | 买入 (P) | Common Stock | 34,722 | USD 5.76 | USD 199,999 | SEC 申报 ↗ |
| 2025-07-21 | Lisi Steven A. | 买入 (P) | Common Stock | 6,000 | USD 3.25 | USD 19,500 | SEC 申报 ↗ |
| 2025-03-14 | Carey Robert | 买入 (P) | Common Stock | 1,000,000 | USD 0.25 | USD 250,100 | SEC 申报 ↗ |
| 2025-02-19 | Gaul Michael A. | 买入 (P) | Common Stock | 6,000 | USD 0.38 | USD 2,280 | SEC 申报 ↗ |
| 2024-09-26 | Lisi Steven A. | 买入 (P) | Common Stock | 1,476,626 | USD 0.50 | USD 738,313 | SEC 申报 ↗ |
| 2024-09-26 | Carey Robert | 买入 (P) | Common Stock | 1,476,626 | USD 0.50 | USD 738,313 | SEC 申报 ↗ |
| 2024-08-15 | Lisi Steven A. | 买入 (P) | Common Stock | 50,000 | USD 0.37 | USD 18,500 | SEC 申报 ↗ |
| 2024-08-14 | Lucera Erick | 买入 (P) | Common Stock | 39,266 | USD 0.40 | USD 15,706 | SEC 申报 ↗ |
| 2024-08-14 | Lisi Steven A. | 买入 (P) | Common Stock | 100,000 | USD 0.39 | USD 39,000 | SEC 申报 ↗ |
| 2024-08-14 | Carey Robert | 买入 (P) | Common Stock | 100,000 | USD 0.40 | USD 40,000 | SEC 申报 ↗ |
Form 4 申报证据
6 transaction lines in the latest 365-day window; 164 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Lin Yi-Chien | 买入 (P) | Common Stock | 2,607 | USD 2.21 | USD 5,761 | SEC 申报 ↗ |
| 2026-10-01 | Lin Yi-Chien | 买入 (P) | Common Stock | 15,393 | USD 2.80 | USD 43,100 | SEC 申报 ↗ |
| 2026-09-30 | Lin Yi-Chien | 买入 (P) | Common Stock | 2,000 | USD 2.71 | USD 5,420 | SEC 申报 ↗ |
展开近期 Form 4 证据 (6 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Lin Yi-Chien | 买入 (P) | Common Stock | 2,607 | USD 2.21 | USD 5,761 | SEC 申报 ↗ |
| 2026-10-01 | Lin Yi-Chien | 买入 (P) | Common Stock | 15,393 | USD 2.80 | USD 43,100 | SEC 申报 ↗ |
| 2026-09-30 | Lin Yi-Chien | 买入 (P) | Common Stock | 2,000 | USD 2.71 | USD 5,420 | SEC 申报 ↗ |
| 2026-09-29 | Lin Yi-Chien | 买入 (P) | Common Stock | 3,000 | USD 2.69 | USD 8,070 | SEC 申报 ↗ |
| 2026-07-29 | MOORHEAD DANIEL J | 买入 (P) | Common Stock | 4,340 | USD 5.76 | USD 24,998 | SEC 申报 ↗ |
| 2026-07-29 | Goodman Robert Scott | 买入 (P) | Common Stock | 34,722 | USD 5.76 | USD 199,999 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | XAIR |
| CIK | 0001641631 |
| 行业 | Healthcare |
| 细分行业 | Medical Devices Yahoo Finance |
| SEC SIC | 3841 Surgical & Medical Instruments & Apparatus |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 164 transaction lines from 2020-06-25 to 2026-10-13 74 P purchase lines · 60 S sale lines · 30 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.